Arabic Arabic English English French French German German
dark

AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery

AcelRx Pharmaceuticals, Inc. today announced the publication of an editorial regarding the use of sufentanil sublingual tablet (SST; DSUVIA®) in total joint replacement surgery. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Conference Call on Report on Operations 2021

Next Post

Perceval: CORCYM Announces the First Patient Implanted in China

Related Posts
Total
0
Share